A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Dasatinib (Primary) ; Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2017 Planned primary completion date changed from 1 Jan 2010 to 1 Dec 2009.
- 14 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment as Unable to enroll.
- 10 Jun 2017 Biomarkers information updated